763 Initial results from phase I dose escalation trial of CAN1012 in patients with solid tumor malignancies

• Ning Li,
• William L Redmond,
• Brendan Curti,
• Shuhang Wang,
• Herui Yao,
• Erwei Song,
• Henry Yu,
• Giorgio Massimini,
• Ming-Hong Hu,
• Rongliang Lou,
• Wanping Geng,
• Sanlong Wang,
• Meiling Zhang,
• Rongchu Chen,
• Baotian Qin,
• John Mao,
• Shaoshan Wang

Affiliations

Ning Li

3Chinese Academy of Medical Sciences, Beijing, China

William L Redmond

7Earle A. Chiles Research Institute, Providence Cancer Institute, Portland, OR, USA

Brendan Curti

5Providence Cancer Institute, Franz Clinic, Portland, OR, USA

Shuhang Wang

4Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China

Herui Yao

2Sun Yat-sen Memorial Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China

Erwei Song

11Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, Guangdong, China

Henry Yu

1CanWell Pharma Inc, Woburn, MA, USA

Giorgio Massimini

1CanWell Pharma Inc, Woburn, MA, USA

Ming-Hong Hu

6CanWell Pharma Inc., Woburn, MA, USA

Rongliang Lou

1CanWell Pharma Inc, Woburn, MA, USA

Wanping Geng

8CanWell Pharma, Woburn, MA, USA

Sanlong Wang

1CanWell Pharma Inc, Woburn, MA, USA

Meiling Zhang

1CanWell Pharma Inc, Woburn, MA, USA

Rongchu Chen

1CanWell Pharma Inc, Woburn, MA, USA

Baotian Qin

1CanWell Pharma Inc, Woburn, MA, USA

John Mao

9JWM Pharma, San Francisco, CA, USA

Shaoshan Wang

10Canwell Pharma Inc, Newton, MA, USA